670 related articles for article (PubMed ID: 36451815)
1. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
2. Construction and validation of a cuproptosis-related lncRNA prognosis signature in bladder carcinoma.
Song J; Sun X; Wang T; Yan L; Su P; Yuan L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11207-11221. PubMed ID: 37354222
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
Zhu S; Li H; Fan Y; Tang C
BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
[TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
5. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
6. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
7. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
8. A novel cuproptosis-related lncRNAs signature predicts prognosis in bladder cancer.
Wu L; Chen W; Cao Y; Chen B; He Y; Wang X
Aging (Albany NY); 2023 Jul; 15(13):6445-6466. PubMed ID: 37424068
[TBL] [Abstract][Full Text] [Related]
9. A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients.
Jiang S; Zhang J; Fan Q; Li Z; Dou R; Lin Z; Chen Z; Xu Y; Huang Z; Lan J; Lin W; Xu S; Gao X; Li M
Hum Cell; 2023 Mar; 36(2):798-811. PubMed ID: 36709471
[TBL] [Abstract][Full Text] [Related]
10. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
11. Construction of a cuproptosis-associated lncRNA prognostic signature for bladder cancer and experimental validation of cuproptosis-related lncRNA UBE2Q1-AS1.
Shen J; Du M; Liang S; Wang L; Bi J
Front Med (Lausanne); 2023; 10():1222543. PubMed ID: 37614950
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of cuproptosis-related lncRNAs in the prognosis and therapy response of patients with bladder cancer.
Li D; Wu X; Fan X; Cheng C; Li D; Zhang W
Ann Transl Med; 2022 Nov; 10(22):1232. PubMed ID: 36544685
[TBL] [Abstract][Full Text] [Related]
14. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
Zhu Y; He J; Li Z; Yang W
BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
[TBL] [Abstract][Full Text] [Related]
16. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
18. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
19. Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.
Xu C; Chen A; Mao C; Cui B
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):139-147. PubMed ID: 37283097
[TBL] [Abstract][Full Text] [Related]
20. A novel cuproptosis-related lncRNAs signature predicts prognostic and immune of bladder urothelial carcinoma.
Zhou Z; Zhou Y; Liu W; Dai J
Front Genet; 2023; 14():1148430. PubMed ID: 37065485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
